Shares of Paratek Pharmaceuticals Inc. (PRTK) rose 3.4% to $26.25 in premarket trading on Friday, Oct. 6, on microbiology data from its Phase 3 Optic study of omadacycline, an investigational antibiotic.
The data show that omadacycline is "active against the clinically important typical and atypical community-acquired bacterial pneumonia (CABP) pathogens," said Boston-based Paratek in the Oct. 6 announcement.
"These microbiology data add to our growing understanding of the clinical and in vitro activity of omadacycline, and lay a foundation for clinicians for its potential use in the CABP setting where microbiological confirmation of infection is difficult and a pathogen is only identified in less than 10 percent of patients," said Paratek president, chief operating officer and chief medical officer Evan Loh, M.D., in a statement.
Also on Friday, Paratek unveiled the results of three sub-analyses from the Phase 3 Oasis-1 study of omadacycline. The data show a "consistent safety and efficacy profile" of omadacycline when treating acute bacterial skin and skin structure infections in patients with comorbid conditions, the company said.
The data "demonstrate that dosing adjustments should not be required for patients with comorbid conditions," Loh said in the announcement.
Meanwhile, shares of Flexion Therapeutics Inc. (FLXN) rose 3.2% to $28 as investors await the fate of Flexion's lead product candidate Zilretta as a potential treatment for osteoarthritis of the knee.
In February, Burlington, Mass.-based Flexion said the U.S. Food and Drug Administration had accepted for filing Flexion's new drug application for Zilretta and the agency established Oct. 6 as the Prescription Drug User Fee Act (PDUFA) date. The PDUFA date is a deadline for the FDA to approve a new drug.
Among the other biotech stock movers was Sangamo Therapeutics Inc. (SGMO) , down 5.4% to $15.75.